Methods: PHIV and PHEU children in the Pediatric HIV/AIDS Cohort Study had total body (TB) and lumbar spine (LS) BMD and bone mineral content (BMC) measured by dual-energy x-ray absorptiometry; BMD z-scores (BMDz) were calculated for age and sex. Low 25(OH)D was defined as #20 ng/mL and high PTH as .65 pg/mL. We fit linear regression models to estimate the average adjusted differences in BMD/BMC by 25(OH)D and PTH status and log binomial models to determine adjusted prevalence ratios of low 25(OH)D and high PTH in PHIV relative to PHEU children. 
INTRODUCTION
Adequate attainment of peak bone mass by young adulthood decreases the risk of osteoporosis and fragility fractures later in life, 1 and it can be optimized with adequate intakes of calcium, phosphorus, and vitamin D, sunlight exposure, and regular physical activity. 1 Bone mineralization may be adversely affected by delays in growth and puberty, nutrient malabsorption, and chronic infections and inflammation, including HIV. Children with perinatally acquired HIV (PHIV) have lower bone mineral density (BMD) compared with healthy children 2 and perinatally HIV-exposed uninfected (PHEU) children. 3 There remains a paucity of information regarding factors underlying the observed low BMD in PHIV children.
It is likely that low vitamin D status, as reflected by low serum levels of 25-hydroxy vitamin D [25(OH)D] and suggested by elevated parathyroid hormone (PTH) levels, contributes to suboptimal bone accumulation in PHIV children. Studies in HIV-infected adults report low 25(OH) D in 13%-77% of participants 4, 5 and associations of low 25 (OH)D with bone loss. 6 Among the few studies conducted in HIV-infected children and adolescents, the prevalence of low 25(OH)D ranged from 21% to 39% in PHIV adolescents [7] [8] [9] [10] [11] and $50% in adolescents behaviorally infected by HIV. 12, 13 In PHIV adolescents, lumbar spine (LS) BMD was lower in those with both low 25(OH)D and high PTH. 11 In HIVinfected adults, 25(OH)D levels were lower among those initiating antiretroviral therapy (ART) with efavirenz (EFV) compared with those without initiating ART without EFV, 14 and baseline PTH levels were higher in HIV-infected adolescents receiving ART with tenofovir (TDF) compared with those not receiving ART with TDF. 12 Few studies have evaluated the relationship of low 25 (OH)D and high PTH on bone outcomes in large cohorts of PHIV and PHEU children. 11 The primary objectives of this cross-sectional study were to (1) evaluate associations of low 25(OH)D and high PTH concentrations with total body (TB) and spine BMD and bone mineral content (BMC) and (2) assess distributions of 25(OH)D and PTH by HIV status and exposure to EFV and TDF.
METHODS
The Adolescent Master Protocol of the NIH-supported Pediatric HIV/AIDS Cohort Study (PHACS) evaluates outcomes of HIV infection and ART among PHIV compared with PHEU preadolescents and adolescents across 15 clinical sites. The protocol was approved by the Institutional Review Boards at each site and the Harvard T.H. Chan School of Public Health. Informed consent from the parent(s) or guardian(s) and assent from participants were obtained per local institutional review board guidelines.
DATA COLLECTION Sociodemographic and Clinical History
Clinical and laboratory data, including sociodemographics and Tanner staging, were obtained as previously described. 15 Tanner stage was ascertained by inspection of breasts and pubic hair for females and of genitalia and pubic hair for males at semiannual visits until Tanner stage 5 was reached. For boys and girls, the more advanced stage of the 2 respective pubertal components was used for classification if there was discordance between the examined body sites (eg, breast vs. pubic hair in females). Weight, height, and body mass index were expressed as z-scores. 16 Season at the time of blood draw was categorized as winter, spring, summer, or fall based on solstice dates. Latitude was considered both as a categorical [sites classified as northern ($39 degree) or southern (,39 degree)] and a continuous variable.
Continental Ancestry
Because circulating levels of both 25(OH)D and BMD vary by race, we included genetic ancestry informative markers to adjust for residual confounding in addition to self-reported race and ethnicity. A panel of 41 singlenucleotide polymorphisms ancestry informative markers was used to determine continental ancestry, which was estimated by comparing each child's genotype to allele frequencies in a reference set of 3517 individuals. 17 Reference populations were originally grouped into the 7 world regions: Europe, Africa, America, Central/South Asia, South/West Asia, East Asia, and Oceania. We determined the percentage of each region present within an individual, which totals 100%. 18, 19 Because of the small number of Asians in the study, we combined Europe, Central/South Asia, and South/West Asia (Europe/CSW Asia) by adding the regional ancestry percentage.
Bone Outcomes
TB-BMD including head, and LS-BMD, TB-BMC including head (TB-BMC) and excluding head (TBLH-BMC), LS-BMC, percent body fat (%), and extremity lean mass (g) were measured on a Lunar or Hologic dual energy x-ray absorptiometry (DXA) scanner (General Electric Healthcare, Buckinghamshire, United Kingdom or Hologic, Inc, Bedford, MA) as previously described. 3 A phantom was circulated to each clinical site to standardize results. Scans were sent to the Body Composition Analysis Center at the Tufts University School of Medicine for central analysis and standardization. Hologic scans were analyzed using Hologic QDR version 12.3 and APEX version 3.3. Lunar scans were analyzed using Prodigy Advance enCORE 2005 version 9 and enCORE 2011 version 13.6. All scans were analyzed by a single technician blinded to the HIV status of the participants. Bone age (BA) was assessed using x-rays of the left hand and wrist by a radiologist at each clinical site blinded to HIV status, and TB and LS BMD z-scores for age and sex (BMDz) were calculated using normative BMD data. 3, 20 For children between Tanner stages 1 and 4 with a chronologic age (CA) that differed by more than 1 SD from the BA, the BA was used instead of the CA in the TB-BMD and LS-BMD calculations. 3 For children at Tanner stage 5, CA was used. Children between Tanner stages 1 and 4 were excluded from analyses of BMDz if their BA was missing.
Laboratory Measures
For this cross-sectional analysis, we selected a repository blood specimen (see Table, Database records from children with high PTH and/or high phosphate levels (.5.4 mg/dL) were reviewed for evidence of concurrent clinical diseases (pancreatitis, chronic kidney disease, inflammatory bowel disease, neonatal renal failure, and nephrolithiasis).
Dietary Recall and Physical Activity
The Block Dietary Questionnaire and Physical Activity Screener for Children and Adolescents were administered to assess dietary intake including supplement use and physical activity, respectively, over the past week (Nutriquest; Block Dietary Data Systems, Berkeley, CA). The recommended daily dietary allowance for calcium was $1100 mg for those aged 4-8 years and $1300 mg for those aged 9-18 years, and vitamin D was $600 IU/d for those aged 1-18 years of age. 22 Minutes of vigorous physical activity were categorized into .75th percentile (.25.2 min/d) or #75th percentile (#25.2 min/d) based on our data distribution.
Statistical Methods
The distribution of socioeconomic and clinical covariates by HIV, 25(OH)D, and PTH status was compared using Wilcoxon test or Kruskal-Wallis for continuous and x 2 for categorical variables. A variable was constructed for combinations of low 25(OH)D and high PTH.
Linear regression models were fit with the robust variance to evaluate differences in bone outcomes by 25 (OH)D and PTH status in PHEU and PHIV separately. Effect modification of 25(OH)D by HIV status was tested in models that included both PHIV and PHEU children. Potential confounders were chosen a priori based on the literature review and expert knowledge. Adjusted models of bone outcomes included age at vitamin D measure, black race, continental ancestry (African, Europe/CSW Asia, and other), height z-score, extremity lean mass, and vigorous activity .75th percentile. We additionally adjusted for percent body fat when 25(OH)D status was the exposure and for Tanner stage and sex when the outcome was TB-BMC, TBLH-BMC, or LS-BMC. We did not include season and latitude as potential confounders because we did not hypothesize an effect on bone other than through 25(OH)D. Missing indicators were included for those missing information about race and vigorous activity.
Log binomial regression models were fit to obtain the unadjusted and adjusted prevalence ratios (aPR) of low 25 (OH)D and high PTH in PHIV compared with PHEU children and for current TDF and EFV use compared with PHEU children. When the log binomial model did not converge, a Poisson model was fit. 23 To estimate average differences in 25(OH)D and PTH levels by the above groups, we fit linear regression models with a robust variance estimator. All models were adjusted for black race and continental origin. 25(OH)D models were additionally adjusted for season and latitude. PTH levels may be higher in TDF users possibly because of phosphate wasting. Thus, as a secondary aim, we fit linear regression models to determine the relationship of PTH with calcium levels by HIV and TDF status. PHIV children without antiretroviral information or not using antiretrovirals at the 25(OH)D assessment were excluded from analyses of EFV or TDF. Analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC). The distribution and unadjusted comparison of socioeconomics, lifestyle characteristics, anthropometrics, and laboratory values between PHIV and PHEU children are shown in Table 1 . The prevalence of low 25(OH)D was 40% overall and higher in PHIV compared with PHEU (42% vs. 34%). Average PTH concentrations were higher in PHIV, and 9% of PHIV and 2% of PHEU had high PTH. Among PHIV with high PTH and without low 25(OH)D, the range of 25 (OH)D levels was 21.1-25.5 ng/mL in 10 children, 29.4-32.6 ng/mL in 4 children, and 52.4 ng/mL in 1 child.
RESULTS

Characteristics
Diagnoses Among Children With High PTH and/or Phosphate Levels
Among the 50 children with high PTH and/or high phosphate, only 1 child had a relevant clinical diagnosis other than HIV (ie, chronic kidney disease). That child was included in all analyses. None of the PHEU children had a relevant diagnosis.
Association of 25(OH)D and PTH With Bone
Among PHIV children ( Similar results were observed for TBLH-BMC. Among PHEU children, adjusted TB-BMD z-scores were on average 0.34 SD lower (95% CI, 20.64 to 20.03) in children with low 25(OH)D, but there were no differences in TB-BMC and TBLH-BMC. In models including PHIV and PHEU children, there was no strong indication of effect modification of HIV status by low 25(OH) for any of the bone outcomes (P . There was no apparent difference in any bone outcome by PTH status among PHIV children ( Table 2 ). The average difference in TB-BMD z-scores was 20.02 (95% CI, 20.37 to 0.42) between those with high versus normal PTH. However, TB-BMD z-scores were on average 0. 48 *Missing data for PHIV and PHEU: Hispanic (n = 1, n = 3), black race (n = 21, n = 6), birthplace (n = 2, nN = 0), vigorous activity (n = 79, n = 14), dietary intake (n = 26, n = 8), Tanner stage (n = 2, n = 2), PTH (n = 0, n = 1), calcium (n = 5, n = 0), phosphate/creatinine (n = 1, n = 0), CD4 count (n = 2), and HIV viral load (n = 0).
†Continental origin (%)-The percent for each region is the percent present within an individual for that region. When looking by HIV status, it is the median of those individual percents for that region.
‡Northern: $39-degree latitude. §The recommended daily dietary allowance for calcium is 1100 for children 4-8 years old and 1300 for children 9-18 years old. kNo percent body fat measured (n = 21 PHIV, n = 8 PHEU) because there was no DXA scan within 365 days of the 25(OH)D. ¶If Tanner stage was missing at the time of 25(OH)D assessment, we carried forward the Tanner stage assessment from the previous annual or semiannual visit, except for 4 children on which there was no previous Tanner stage assessment in the Adolescent Master Protocol.
#Twelve PHIV children are not included in these numbers. For 8 children, the last information on ARV use was just before the 25(OH)D date; for 2 children, ARV was started for the first time after the 25(OH)D date, and for 2 children, ARVs were never used. Of the 8 children with previous ARV use just before the 25(OH)D date, 1 had been on TDF, 2 on EFV, 1 on TDF and EFV, and 4 on neither TDF or EFV. PHEU children (model 2B), and 0.95 (0.76 to 1.18) in PHIV not receiving EFV compared with PHEU children (Table 4 , model 2B). The opposite trend was observed for PHIV receiving TDF compared with PHEU (aPR, 0.77; 95% CI, 0.56 to 1.06, model 3B). Differences in mean 25(OH)D levels by HIV, and by EFV and TDF use, suggest similar results (Table 4 , models 7B-9B).
Prevalence of High PTH in PHIV Compared
With PHEU Children PHIV had a 3.17 (1.25 to 8.06) times greater adjusted prevalence of high PTH than PHEU children (Table 4 , model 4B). The average difference between groups was 5.26 pg/mL (2.35 to 8.17). PHIV who were not receiving EFV (Table 4, model 5B) had a 3.67 times higher prevalence of high PTH than PHEU children (1.44 to 9.36). The prevalence of high PTH (Table 4 , model 6B) was 5.50 (1.95 to 15.49) times higher in PHIV receiving TDF compared with PHEU children and 2.64 times higher in PHIV not receiving TDF (1.01 to 6.94) than in PHEU children. Compared with PHEU, PTH concentrations were on average 5.54 pg/mL higher in PHIV not receiving EFV (Table 4 , model 11B) and 11.65 pg/mL higher in those receiving TDF (Table 4 , model 12B), compared with PHEU children.
Relationship Between Calcium and PTH by HIV Status and TDF Use
Serum calcium and PTH were negatively associated in PHIV not receiving TDF (slope, 210.5; P = 0.001) and PHEU (slope, 27.6; P = 0.002) but not associated among PHIV receiving TDF (slope, 23. 
DISCUSSION
In this multicenter cohort of PHIV and PHEU children in the United States, 40% had vitamin D deficiency overall, and the prevalence did not differ by HIV status after careful adjustment for confounding. In both PHIV and PHEU children, low 25(OH)D was associated with lower TB-BMD but not with LS-BMD in either cohort. PTH levels were highest in PHIV children receiving TDF. Although PTH levels were, on average, higher in PHIV children with low 25 (OH)D, high PTH was only associated with lower TB-BMD when accompanied by low 25(OH)D. The relationship between calcium and PTH was weak in PHIV children receiving TDF.
Several randomized clinical trials have been done examining the effects of vitamin D supplementation on healthy children and adolescents. 24 A meta-analysis of 6 such randomized clinical trials found that children with normal baseline 25(OH)D concentrations (.18 ng/mL) did not have benefits in BMD accrual from supplementation but that there was a significant positive effect of supplementation on TB and a borderline significant effect on spine BMD among those with low levels of 25(OH)D at baseline. 25 Four cross-sectional studies of the relationship of 25(OH)D as a continuous variable with BMD in normal children found positive associations with whole-body BMD, 26 †No models were fit for high PTH among PHEU children because only 5 had high PTH. ‡Adjusted models of bone outcomes included age at vitamin D measurement, black race, ancestral markers (African, Europe/CSW Asia, other), height z, extremity lean mass, vigorous activity .75th percentile, and CD4 count. When 25(OH)D status was the exposure, we additionally adjusted for percent body fat. When the outcome was TB-BMC, TB less head-BMC or LS-BMC, we additionally adjusted for Tanner stage and sex.
associations were found in 5 other cross-sectional studies. [30] [31] [32] [33] [34] We previously found that TB-BMD was greater in PHIV children using vitamin supplements. 35 In a study of vitamin D and calcium supplementation over 2 years in PHIV children, 25(OH)D levels increased, but this did not significantly increase TB or spine BMC or BMD measures over time. 7 In the aforementioned study, those who advanced through puberty during the study period had a greater increase in TB-BMC and LS-BMC in the supplemented group, but this result did not achieve significance. Thus, our finding that low 25 (OH)D was associated with decreased TB BMD and BMC is supported by some, but not all, studies. Because the effect sizes on BMD from vitamin D supplementation appear to be modest, and many prior studies have used low doses of vitamin D supplementation (as little as 133 IU/day) and included children who at baseline were vitamin D replete, further adequately powered studies examining the effects of vitamin D supplementation to target adequate 25(OH)D serum concentrations across puberty, particularly in children with PHIV with baseline vitamin D deficiency or insufficiency, are needed.
It is unclear why we found no associations with LS-BMD/BMC in either group or with TB-BMC in PHEU children. In contrast to these studies, we evaluated the effect of categorically low 25(OH)D compared with 25(OH)D as a continuous variable. This is based on clinical evidence that the relationship between 25(OH)D and BMD may not be linear and that those at the lowest levels of 25(OH)D may benefit most from supplementation. 21 The lack of association between high PTH and bone outcomes in our study is possibly a result of competing reasons for higher PTH values, including low 25(OH)D, additional requirements for calcium and phosphate during rapid bone accrual, and effects of TDF on PTH. 12 This is supported by our finding of lower TB-BMD when high PTH was accompanied by low 25(OH)D.
Vitamin D deficiency is common in the United States. [36] [37] [38] The 40% prevalence of low 25(OH)D in our cohort was similar to those of cohorts of healthy children in the northeastern United States 37 and PHIV children in New York City. 7 Our prevalence of vitamin D deficiency was higher than the 24% observed in 6-to 18-year-old children in the National Health and Nutrition Examination Survey representative US sample of this age group, 38 but lower than the $50% reported in behaviorally HIV-infected adolescents. 12, 13 Differences across studies are likely attributable to age, race, prevalence of obesity, latitude, sun exposure, season of sampling, and dietary intake.
While low 25(OH)D was equally prevalent in our PHIV and PHEU children overall after adjustment for known confounders, 37,39 low 25(OH)D concentrations may be more common in PHIV receiving EFV than in PHEU children, although our power to detect a significant difference between groups may be too low. This is consistent with adult studies 14 and may be explained by in vitro evidence of EFV induction of the P450 enzyme CYP24, 40 which converts 25(OH)D to its inactive form, calcitroic acid. PHIV children had higher vitamin D intake than did PHEU, but HIV providers may check 25(OH) D levels in their PHIV patients and recommend supplementation.
Calcium is important to optimize bones and tooth mineralization and for catalytic and mechanical functions throughout the body. The body tightly regulates ionized calcium levels. When the calcium supply is insufficient, PTH concentrations increase. PTH increases serum calcium through a variety of mechanisms. PTH mobilizes calcium adsorbed to the bone surface by breaking down bone mineral and matrix, and it stimulates conversion of 25(OH)D to *Missing data for 25(OH)D #20 ng/mL and .20 ng/mL: black race (n = 7, n = 20), dietary intake (n = 8, n = 26), percent body fat (n = 14, n = 15), PTH (n = 0, n = 1), calcium (n = 4, n = 1), phosphate/creatinine (n = 1, n = 0), EFV/TDF (n = 4, n = 6), and CD4 count (n = 0, n = 2).
†Northern latitude: $39-degree latitude. ‡No percent body fat measure because there was no TB DXA scan performed within 365 days of 25(OH)D (n = 14, n = 15).
§Twelve PHIV children are not included in these numbers. For 8 children, the last information on ARV use was just before the 25(OH)D date; for 2 children, ARV was started for the first time after the 25(OH)D date, and for 2 children, ARVs were never used. Of the 8 children with previous ARV use just before the 25(OH)D date, 1 had been on TDF, 2 on EFV, 1 on TDF and EFV, and 4 on neither TDF or EFV.
1,25-dihydroxyvitamin D (1,25(OH)(2)D), which increases gut calcium absorption and renal calcium reabsorption. During the rapid linear growth and bone accrual of puberty, there is an increased demand for calcium and phosphate, and PTH levels increase. 41, 42 PTH measurements also provide an assessment of the level of "stress" on the system as a result of low 25(OH)D concentrations, although the degree of serum PTH suppression may not determine optimal vitamin D status in children. 43 TDF use has been previously associated with increases in serum concentrations of PTH, 12, 44 with multiple mechanisms implicated. TDF appears to have effects on both bone and hormones, such as fibroblast growth factor-23 and 1,25 (OH)2D, that may indirectly increase PTH. [45] [46] [47] TDF use can also result in renal tubular dysfunction stimulating the production of PTH and in renal phosphate wasting, 44 which may, in part, be PTH mediated. 12 In HIV-infected adolescents, baseline PTH levels were higher in TDF users regardless of 25(OH)D status. With vitamin D supplementation, PTH levels decreased in the TDF group but did not change in those not receiving TDF. 12 In our cohort, PTH levels were higher in those with low 25(OH)D, highest at Tanner stages 3-4, the time of most rapid bone accrual, and higher among TDF users. PTH concentrations were not strongly associated with serum calcium among TDF users, suggesting other mechanisms for elevated PTH.
Our study has several limitations. Although 25(OH)D is a stable vitamin D metabolite with a biological half-life of 2-3 weeks, levels vary by season; thus, one measurement may not represent the average yearly level. 48 However, children with 25(OH)D deficiency at one time of the year tend to be deficient at other times during the year, 49 which favors using the #20 ng/mL cutoff recommended by the Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. 21 Although imperfect, we adjusted for season when evaluating the prevalence or differences in 25(OH)D by subgroups. We recognize that the 20 ng/mL cutoff is based upon what is needed to prevent rickets and osteomalacia, 21 but concentrations required for optimal bone and immunological health are likely higher. 50 Using this lower threshold, we could examine characteristics of those most likely to have clinically significant deficiency. Because this was a cross-sectional study where 25(OH)D, PTH, and DXA parameters were measured within 1 year of each other, we could not establish a temporal relationship between low 25(OH)D or high PTH and subsequent bone accrual. Although this is an important limitation, BMD ranking tracks well over time in Prevalence Ratio (95% CI) P Difference (95% CI) P healthy children such that those who ranked among the lowest earlier in childhood also ranked among the lowest later in adolescence and those who ranked highest generally remained high. 51 When evaluating prevalence of high PTH, confidence intervals were wide because of a few children having high PTH. Finally, our findings might not be generalizable to populations other than those in the United States where there is a difference in the distribution of continental ancestry and nutritional status. Children gain more than half of their peak bone mass during adolescence with the greatest increase following the pubertal growth spurt, highlighting the need to identify modifiable factors during this critical period that could improve bone accrual. This study afforded a unique opportunity to further quantify the risk factors for poor bone health, specifically low 25(OH)D. This may lead to novel vitamin D supplementation trials that could ameliorate deficits and improve bone health at critical developmental stages.
